Critical re-evaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use

By G. Fadini, Douglas Losordo, Stefanie Dimmeler. Circulation Research, 2012

640 citations recorded by the source corpus.

Diverse subsets of endothelial progenitor cells (EPCs) are used for the treatment of ischemic diseases in clinical trials, and circulating EPCs levels are considered as biomarkers for coronary and peripheral artery disease. However, despite significant steps forward in defining their potential for both therapeutic and diagnostic purposes, further progress has been mired by unresolved questions around the definition and the mechanism of action of EPCs. Diverse culturing methods and detection of various combinations of different surface antigens were used to enrich and identify EPCs. These attempts were particularly challenged by the close relationship and overlapping markers of the endothelial and hematopoietic lineages. This article will critically review the most commonly used protocols to define EPCs by culture assays or by fluorescence-activated cell sorter in the context of their therapeutic or diagnostic use. We also delineate new research avenues to move forward our knowledge on EPC biology.

Subfields: Cell Biology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/8700d8cdaf1ec6de19a4a1cfc05b70be8e60ca52

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

  1. L. Dou
  2. Mingjing Yan
  3. Jian Li
  4. Jun Guo
  5. Xiuqing Huang
  6. Weiqing Tang
  7. Tao Shen

Citations in the corpus